Objective; To study the clinical effect of combination treatment with gemcitabine (GEM) and Kanglaite injection on advanced pancreatic cancer. Methods: In this randomized controlled study, to select 64 cases of advanced pancreatic cancer during Jul.2002 to Sep.2008.which included gemcitabine chemotherapy 32 cases (group A),gemcitabine + Kanglaite 32 cases (group B). Results;The rates of clinical benefit response on the 3rd month,the difference of group GEM + Kanglaite injection compared with GEM was not significant ( P > 0. 05 ) ; on the 6th month, group B was higher than group GEM (P < 0. 05). The rates of objective tumor response difference between group B and A was not significant (P>0.05) ,but there was difference in clinical benefit response rate ( P < 0.05) , and adverse events (P<0.05). Conclusion;Treatment of pancreatic cancer with gemcitabine chemotherapy combined Kanglaite injection improved the clinical benefit response side - effect quality of life of advanced pancreatic cancer.%目的:探讨吉西他滨(GEM)联合康莱特治疗晚期胰腺癌的临床疗效.方法:对我院肿瘤治疗中心2002年7月至2008年9月间收治的64例晚期胰腺癌患者进行随机对照研究.32例GEM化疗病人归为A组,32例GEM化疗+康莱特治疗病人归为B组.结果:GEM组和GEM+康莱特组的临床受益率第3周期时差异无统计学意义(P＞0.05)；第6周期时GEM+康莱特组显著高于GEM组,差异有统计学意义(P＜0.05).GEM+康莱特组与GEM组近期有效率差异无统计学意义(P＞0.05),但可提高总临床获益率(P＜0.05),且不良反应差异有统计学意义(P＜0.05).结论:康莱特联合吉西他滨治疗晚期胰腺癌可提高患者临床受益反应率和总临床获益率,降低化疗不良反应,提高生存质量.
展开▼
